Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Yellow fever vaccine seroconversion in travelers.

Literature DB >> 21976582

Yellow fever vaccine seroconversion in travelers.

Allison Kay¹, Lin H Chen, Maggie Sisti, Thomas P Monath.

Abstract

To assess immunity after yellow fever (YF) 17D live-attenuated vaccination, we measured the antibody levels before vaccination and at 21 days and 8 months after vaccination in YF-naïve travelers. Thirty subjects were enrolled in the study, with 100% providing sera at 21 days and 86.6% providing sera at 8 months. All subjects seroconverted by day 21, and the geometric mean titers of the anti-YF antibodies decreased between day 21 and month 8 from 6,451 to 1,246. This study corroborates the high rates of seroconversion achieved by the live-attenuated YF vaccine.

Entities: Disease Species

Mesh：

Substances：

Year: 2011 PMID： 21976582 PMCID： PMC3183787 DOI： 10.4269/ajtmh.2011.11-0363

Source DB: PubMed Journal: Am J Trop Med Hyg ISSN： 0002-9637 Impact factor: 2.345

13 in total

1. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines.

Authors: J Lang; J Zuckerman; P Clarke; P Barrett; C Kirkpatrick; C Blondeau
Journal: Am J Trop Med Hyg Date: 1999-06 Impact factor: 2.345

Review 2. Prevention of yellow fever in persons traveling to the tropics.

Authors: Thomas P Monath; Martin S Cetron
Journal: Clin Infect Dis Date: 2002-04-25 Impact factor: 9.079

3. Immunological studies with group B arthropod-borne viruses. I. Broadened neutralizing antibody spectrum induced by strain 17D yellow fever vaccine in human subjects previously infected with Japanese encephalitis virus.

Authors: C L WISSEMAN; B H SWEET; M KITAOKA; T TAMIYA
Journal: Am J Trop Med Hyg Date: 1962-07 Impact factor: 2.345

4. Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine.

Authors: E C ROSENZWEIG; R W BABIONE; C L WISSEMAN
Journal: Am J Trop Med Hyg Date: 1963-03 Impact factor: 2.345

5. Cases of travel-acquired dengue fever in Denmark 2001-2009.

Authors: L Vinner; C Domingo; A-C B Ostby; K Rosenberg; A Fomsgaard
Journal: Clin Microbiol Infect Date: 2011-07-11 Impact factor: 8.067

6. Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans.

Authors: T P Monath
Journal: Am J Epidemiol Date: 1971-02 Impact factor: 4.897

7. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.

Authors: J D Poland; C H Calisher; T P Monath; W G Downs; K Murphy
Journal: Bull World Health Organ Date: 1981 Impact factor: 9.408

8. Arbovirus studies in Nupeko forest, a possible natural focus of yellow fever virus in Nigeria. I. Description of the area and serological survey of humans and other vertebrate hosts.

Authors: T P Monath; V H Lee; D C Wilson; A Fagbami; O Tomori
Journal: Trans R Soc Trop Med Hyg Date: 1974 Impact factor: 2.184

9. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.

Authors: Thomas P Monath; Richard Nichols; W Tad Archambault; Linda Moore; Ron Marchesani; Jason Tian; Robert E Shope; Nicola Thomas; Robert Schrader; Dean Furby; Philip Bedford
Journal: Am J Trop Med Hyg Date: 2002-05 Impact factor: 2.345

6. The 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T Cells.

Authors: Alan M Watson; L K Metthew Lam; William B Klimstra; Kate D Ryman
Journal: PLoS Pathog Date: 2016-07-27 Impact factor: 6.823

6 in total

Yellow fever vaccine seroconversion in travelers.

1. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines.

Review 2. Prevention of yellow fever in persons traveling to the tropics.

3. Immunological studies with group B arthropod-borne viruses. I. Broadened neutralizing antibody spectrum induced by strain 17D yellow fever vaccine in human subjects previously infected with Japanese encephalitis virus.

4. Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine.

5. Cases of travel-acquired dengue fever in Denmark 2001-2009.

6. Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans.

7. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.

8. Arbovirus studies in Nupeko forest, a possible natural focus of yellow fever virus in Nigeria. I. Description of the area and serological survey of humans and other vertebrate hosts.

9. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.

10. Yellow fever virus. I. Development and evaluation of a plaque neutralization test.

1. Mathematical modeling based on ordinary differential equations: A promising approach to vaccinology.

Review 2. Experimental therapies for yellow fever.

3. Optimization of the cutoff value for a commercial anti-dengue virus IgG immunoassay.

Review 4. Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine.

5. A qualitatively validated mathematical-computational model of the immune response to the yellow fever vaccine.

6. The 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T Cells.